0001515673 1 2026-06-12 2026-06-12 0001515673 2026-06-12 2026-06-12 0001515673 2 2026-06-12 2026-06-12 pure shares iso4217:USD 0001515673 N/A EX-FILING FEES S-8 S-8 ULTRAGENYX PHARMACEUTICAL INC. false false Equity Common stock, $0.001 par value per share true 3000000 21.84 65520000 0.0001381 9048.31 Equity Common stock, $0.001 par value per share true 400000 21.84 8736000 0.0001381 1206.44 74256000 10254.75 0 10254.75 <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement on Form S-8 (this “Registration Statement”) shall also cover any additional shares of common stock, par value $0.001 per share (the “Common Stock”), of Ultragenyx Pharmaceutical Inc. (the “Registrant”) that become issuable under the Ultragenyx Pharmaceutical Inc. 2023 Incentive Plan (as amended and restated, the “2023 Plan”). The “Amount Registered” represents 3,000,000 shares of Common Stock authorized for issuance under the 2023 Plan. The “Proposed Maximum Offering Price Per Unit” and “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, and are based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on June 8, 2026.</span></div></div> <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the Ultragenyx Pharmaceutical Inc. Employment Inducement Plan (as amended, the “Inducement Plan”). The “Amount Registered” represents 400,000 shares of Common Stock authorized for issuance under the Inducement Plan. The “Proposed Maximum Offering Price Per Unit” and “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, and are based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on June 8, 2026.</span></div></div>